THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

16 October 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Raises £1.25 Million to Accelerate Programmes in High-Burden CNS Disorders

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, is pleased to announce that it has successfully raised £1.25 million (gross) through a direct subscription with certain institutional and existing strategic investors (the "Subscription").

The Subscription was priced at £0.0033 per new ordinary share, representing approximately an 13% discount to the closing mid-market price on 15 October 2025, and will result in the issue of 378,787,876 new ordinary shares of £0.001 each ("New Ordinary Shares"). The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares. Application will be made for the New Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange ("Admission"), which is expected to occur on or around 22 October 2025.

Use of Proceeds

Together with the Company's existing resources, the proceeds will enable Solvonis to broaden its research and development activities, deepening its work within addiction and psychiatry while extending early discovery into neurology, establishing a unified focus on high-burden CNS diseases across three strategic pillars: addiction, psychiatry, and neurology.

Through this investment, Solvonis will:

·      Continue advancing its clinical and pre-clinical programmes across these CNS pillars;

·      Expand the reach of its  CNS drug-discovery programme, which integrates computational chemistry, predictive modelling, and laboratory validation to identify and optimise novel small-molecule modulators relevant across its three pillars; and

·      Strengthen internal R&D and translational capabilities to enable deeper evaluation of new targets and mechanisms addressing the unmet needs driving the world's most high-burden CNS disorders.

This fundraise marks the first step in implementing Solvonis' expanded three-pillar CNS strategy and provides a foundation for continued scientific, clinical, and partnering progress across the Company's diversified pipeline.

Anthony Tennyson, Chief Executive Officer, commented "This financing marks an important time  for Solvonis as we evolve into a broader CNS biopharmaceutical company. Our focus now spans addiction, psychiatry, and neurology - three interlinked areas of enormous unmet need. The continued support of our core investors enables us to accelerate our discovery work and deepen our development programmes across these pillars, advancing our mission to deliver innovative therapies for high-burden CNS disorders."

Admission and Total Voting Rights

Application will be made for the New Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange and to listing in the FCA's Official List Equity Shares (transition) category ("Admission"). It is expected that Admission will become effective at 8.00 a.m. on or around 22 October 2025.

Following Admission, the Company's issued ordinary share capital will comprise 6,782,767,131 ordinary shares of £0.001 each. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com

Singer Capital Markets (Broker)
Phil Davies
+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system (CNS) disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds across addiction, psychiatry, and neurology.

The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with additional discovery work supporting expansion into broader CNS indications. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in the UK, while SVN-002 is preparing for a Phase 2b trial in the US targeting moderate-to-severe AUD. The preclinical PTSD programme (SVN-SDN-14) leverages novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

In parallel, Solvonis is advancing proprietary CNS discovery programmes built on a dedicated compound library to identify new small-molecule modulators of key neurotransmitter systems. This platform enables efficient early-stage innovation and supports the Company's integrated approach to developing therapies across its three strategic pillars.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to deliver sustained value through innovation in CNS therapeutics.

solvonis.com | LinkedIn | X (Twitter)